Merck Jumps On Neurostim Technology, Signing Agreements With Start-Ups
The biotech giant signed a commercial agreement with bioelectronics company Innervia, and the two will work collaboratively on vagus nerve stimulating technologies.
You may also be interested in...
In the third quarter of 2021, medical device company M&A values reached $7.1bn, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $6.7bn.
Medtech Insight spoke to two CEOs of start-ups working on graphene-based devices to learn more about how regulation and fears over nanomaterials’ side effects affect device development.
By utilizing the properties of graphene, INBRAIN hopes to develop improved electrodes implanted in the brain, raising the potential of neuromodulation for treating complex neurological disorders.